Last reviewed · How we verify
Lupron Trigger
Lupron Trigger is a GnRH agonist that causes a surge in luteinizing hormone (LH) to trigger final oocyte maturation and ovulation in assisted reproductive technology cycles.
Lupron Trigger is a GnRH agonist that causes a surge in luteinizing hormone (LH) to trigger final oocyte maturation and ovulation in assisted reproductive technology cycles. Used for Triggering final oocyte maturation and ovulation in assisted reproductive technology (ART) cycles.
At a glance
| Generic name | Lupron Trigger |
|---|---|
| Sponsor | Weill Medical College of Cornell University |
| Drug class | GnRH agonist |
| Target | GnRH receptor |
| Modality | Small molecule |
| Therapeutic area | Reproductive Medicine / Fertility |
| Phase | FDA-approved |
Mechanism of action
Lupron (leuprolide) is a gonadotropin-releasing hormone (GnRH) agonist that, when given as a bolus injection, induces a rapid surge in LH secretion. This LH surge mimics the natural ovulatory trigger and causes the final maturation of oocytes and rupture of the ovarian follicle, allowing egg retrieval in fertility treatment protocols. It is used as an alternative to human chorionic gonadotropin (hCG) in controlled ovarian hyperstimulation cycles.
Approved indications
- Ovulation trigger in assisted reproductive technology (ART) and in vitro fertilization (IVF) cycles
Common side effects
- Ovarian hyperstimulation syndrome (OHSS)
- Injection site reactions
- Headache
- Abdominal discomfort
Key clinical trials
- DeADT - Living Well With Prostate Cancer (NA)
- Assessing Ketorolac (Toradol) at Oocyte Retrieval (PHASE1)
- Prolonged Protocol of Early Follicular or Mid Luteal Phase (NA)
- Study of Dual Trigger Ovulation in Oocyte Donors (PHASE4)
- Gene Expression Profile After Gonadotropin Releasing Hormone (GnRH) Agonist Trigger of Oocyte Maturation (PHASE4)
- Natural Cycle In Vitro Fertilization
- Efficacy of Recombinant FSH/GnRH Antagonist Protocol With and Without LH Adjunct for Egg Bank Donation (PHASE4)
- Does Letrozole Improve the Outcomes and/or Reduce the Cost of IVF-ET Cycles? (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lupron Trigger CI brief — competitive landscape report
- Lupron Trigger updates RSS · CI watch RSS
- Weill Medical College of Cornell University portfolio CI